Asia Pacific Cardiac Marker Testing Market

Asia Pacific Cardiac Marker Testing Market Size (2024 to 2029)

The Size of the Asia Pacific Cardiac Marker Testing Market is valued at USD 0.49 billion in 2024 and is expected to grow to USD 0.85 billion by 2029, registering a CAGR of 11.7% during the forecast period 2024 to 2029.

An increasing number of clinical studies for cardiac biomarker detection and public-private collaborations for cardiac biomarker research are driving the market for cardiac marker testing.

An increase in heart-related diseases and substantial product research and development projects are driving market demand. Consumers are more aware of early detection and the growing need to avoid cardiovascular illnesses such as heart failure, heart attacks, and Acute Coronary Syndrome (ACS). Several Asian Pacific organizations are increasing financing for clinical investigations and research on cardiac marker identification.

Growth in point-of-care testing and rising demand for the most up-to-date treatment processes propel the market forward. In addition, the market is also growing as people become more aware of the benefits of early detection and prevention of heart disorders, including heart attacks.

BNP, along with hs-TNI, - HBDH, CK-MB, and LDH, operates as a predictive biomarker in COVID-19 individuals with or without pre-existing coronary artery disease. With all of these factors in mind, the Asia Pacific Cardiac Marker Testing Market has had moderate growth during the pandemic and is anticipated to increase in the following years. Therefore, these factors will drive the Asia Pacific Cardiac Marker Testing market.

Unfavorable reimbursement policies and strict government rules and regulations are limiting the growth of the Asia Pacific cardiac marker testing market. The cardiac markers aren't employed to diagnose the heart's myocardial blood supply or the tissue location where death occurs. Factors that limit expansion include issues with sample storage and preservation and the amount paid in compensation for suffering. The market is driven by correct and early outcomes and cardiac POC testing.

The cardiac marker testing market witnessed short-term negative growth during COVID-19, which might be attributed to more than a 50% decline in patients with cardiovascular disorders and those diagnosed with myocardial infarction.

This research report on the Asia Pacific Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories.

Asia Pacific Cardiac Marker Testing Market Analysis By Type

• Troponin I & T
• CK-MB
• Myoglobin
• BNP
• hs-CRP

Asia Pacific Cardiac Marker Testing Market Analysis By Product

• Reagent
• Instrument
  • Chemiluminescence
  • Immunofluorescence
  • Immunochromatography
  • ELISA

Asia Pacific Cardiac Marker Testing Market Analysis By Disease

• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure

Asia Pacific Cardiac Marker Testing Market Analysis By Testing

• Lab
• POC

Asia Pacific Cardiac Marker Testing Market Analysis By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the market for cardiac marker testing in the Asia Pacific is expected to develop at the quickest rate. Higher healthcare spending by a more extensive population base, modernization of healthcare infrastructure, and increased penetration of cutting-edge clinical laboratory technologies (mainly in rural regions) are driving the Asia Pacific market.

The India Cardiac Marker Testing Market is predicted to expand at significant growth among all regions of the globe due to variables such as Y-O-Y growth in CVD incidence and a rapid rise in the aging population throughout the forecast period.

The China Cardiac Marker Testing Market is predicted to dominate market share due to the growing understanding of sophisticated technologies among lab workers and cardiologists because of frequent conferences and seminars.

The market growth in APAC is accelerating due to public and private sector initiatives to raise awareness about early disease diagnosis. As a result, according to estimates, annual cardiovascular incidents in China are expected to increase by more than 50% between 2010 and 2030. 

As a result, the cardiac marker testing market is booming in APAC, especially in Japan and India. Improving healthcare infrastructure, a significant patient population, and increasing funding and investments for cardiac analyzer upgrades propels the APAC region's market expansion.

KEY MARKET PLAYERS

Notable companies leading the Asia Pacific Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd.,  Siemens AG, Danaher Corporation, Alere Inc., and Guangzhou Wondfo Biotech Co. Ltd, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, bioMérieux SA, Abbott Laboratories.,